(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP3K6 mRNA] CTD PMID:31150632 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of MAP3K6 mRNA CTD PMID:30723492 17beta-estradiol increases expression ISO RGD:1312171 6480464 Estradiol results in increased expression of MAP3K6 mRNA CTD PMID:19484750 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1312170 6480464 Dihydrotestosterone results in increased expression of MAP3K6 mRNA CTD PMID:29581250 2,2',4,4'-Tetrabromodiphenyl ether decreases expression EXP 6480464 2 more ... CTD PMID:27291303 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1312171 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP3K6 mRNA CTD PMID:17035482 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1312170 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP3K6 mRNA CTD PMID:26238291 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1312171 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAP3K6 mRNA CTD PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1312171 6480464 Tetrachlorodibenzodioxin affects the expression of MAP3K6 mRNA CTD PMID:21570461 2,4,6-trinitrobenzenesulfonic acid decreases expression EXP 6480464 Trinitrobenzenesulfonic Acid results in decreased expression of MAP3K6 mRNA CTD PMID:23537331 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of MAP3K6 mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of MAP3K6 mRNA CTD PMID:21346803 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1312170 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K6 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K6 mRNA CTD PMID:28628672 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid decreases expression ISO RGD:1312170 6480464 Am 580 results in decreased expression of MAP3K6 mRNA CTD PMID:16982809 5-aza-2'-deoxycytidine affects expression ISO RGD:1312170 6480464 Decitabine affects the expression of MAP3K6 mRNA CTD PMID:23300844 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of MAP3K6 mRNA CTD PMID:24780913 acetamide increases expression EXP 6480464 acetamide results in increased expression of MAP3K6 mRNA CTD PMID:31881176 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of MAP3K6 mRNA CTD PMID:28959563 aflatoxin B1 increases methylation ISO RGD:1312170 6480464 Aflatoxin B1 results in increased methylation of MAP3K6 gene CTD PMID:28458013 all-trans-retinoic acid increases expression EXP 6480464 Tretinoin results in increased expression of MAP3K6 mRNA CTD PMID:20488242 anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions ISO RGD:1312171 6480464 pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MAP3K6 mRNA] CTD PMID:17460151 antirheumatic drug decreases expression ISO RGD:1312170 6480464 Antirheumatic Agents results in decreased expression of MAP3K6 mRNA CTD PMID:24449571 arsane decreases expression ISO RGD:1312171 6480464 Arsenic results in decreased expression of MAP3K6 mRNA CTD PMID:19654921 arsenic atom decreases expression ISO RGD:1312171 6480464 Arsenic results in decreased expression of MAP3K6 mRNA CTD PMID:19654921 atrazine decreases expression ISO RGD:1312170 6480464 Atrazine results in decreased expression of MAP3K6 mRNA CTD PMID:22378314 benzo[a]pyrene increases expression ISO RGD:1312171 6480464 Benzo(a)pyrene results in increased expression of MAP3K6 mRNA CTD PMID:20504355 , PMID:21569818 benzo[a]pyrene increases expression ISO RGD:1312170 6480464 Benzo(a)pyrene results in increased expression of MAP3K6 mRNA CTD PMID:26238291 , PMID:32234424 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of MAP3K6 mRNA CTD PMID:21839799 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1312170 6480464 7 more ... CTD PMID:26238291 benzo[b]fluoranthene increases expression ISO RGD:1312171 6480464 benzo(b)fluoranthene results in increased expression of MAP3K6 mRNA CTD PMID:26377693 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of MAP3K6 mRNA CTD PMID:25181051 bisphenol A multiple interactions ISO RGD:1312170 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K6 mRNA CTD PMID:28628672 bisphenol F multiple interactions ISO RGD:1312170 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K6 mRNA CTD PMID:28628672 buta-1,3-diene increases expression ISO RGD:1312171 6480464 1, 3-butadiene results in increased expression of MAP3K6 mRNA CTD PMID:29038090 C60 fullerene decreases expression EXP 6480464 fullerene C60 results in decreased expression of MAP3K6 mRNA CTD PMID:19167457 cadmium atom increases expression ISO RGD:1312170 6480464 Cadmium results in increased expression of MAP3K6 mRNA CTD PMID:22562489 calciol decreases expression ISO RGD:1312171 6480464 Cholecalciferol results in decreased expression of MAP3K6 mRNA CTD PMID:16508948 carbon nanotube affects expression ISO RGD:1312171 6480464 Nanotubes, Carbon affects the expression of MAP3K6 mRNA, Nanotubes, Carbon analog affects the expression of MAP3K6 mRNA CTD PMID:25554681 carbon nanotube increases expression ISO RGD:1312171 6480464 Nanotubes, Carbon analog results in increased expression of MAP3K6 mRNA, Nanotubes, Carbon results in increased expression of MAP3K6 mRNA CTD PMID:25620056 chloroprene increases expression ISO RGD:1312171 6480464 Chloroprene results in increased expression of MAP3K6 mRNA CTD PMID:23125180 choline multiple interactions ISO RGD:1312171 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP3K6 mRNA CTD PMID:20938992 chromium(6+) affects expression ISO RGD:1312171 6480464 chromium hexavalent ion affects the expression of MAP3K6 mRNA CTD PMID:28472532 ciguatoxin CTX1B affects expression ISO RGD:1312171 6480464 Ciguatoxins affects the expression of MAP3K6 mRNA CTD PMID:18353800 cisplatin affects expression ISO RGD:1312170 6480464 Cisplatin affects the expression of MAP3K6 mRNA CTD PMID:23300844 cisplatin multiple interactions ISO RGD:1312170 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of MAP3K6 mRNA CTD PMID:27392435 cisplatin multiple interactions ISO RGD:1312171 6480464 [Cisplatin co-treated with RELB mutant form] results in decreased expression of MAP3K6 mRNA CTD PMID:23625948 crocidolite asbestos affects expression ISO RGD:1312170 6480464 Asbestos, Crocidolite affects the expression of MAP3K6 mRNA CTD PMID:17331233 dexamethasone increases expression ISO RGD:1312171 6480464 Dexamethasone results in increased expression of MAP3K6 mRNA CTD PMID:22733784 dexamethasone multiple interactions ISO RGD:1312170 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K6 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K6 mRNA CTD PMID:28628672 diazinon affects expression EXP 6480464 Diazinon affects the expression of MAP3K6 mRNA CTD PMID:22546817 dibenz[a,h]anthracene increases expression ISO RGD:1312171 6480464 1 more ... CTD PMID:26377693 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of MAP3K6 mRNA CTD PMID:21266533 dieldrin affects expression EXP 6480464 Dieldrin affects the expression of MAP3K6 mRNA CTD PMID:22546817 dimethylarsinic acid decreases expression ISO RGD:1312171 6480464 Cacodylic Acid results in decreased expression of MAP3K6 mRNA CTD PMID:17441966 dioxygen multiple interactions ISO RGD:1312171 6480464 [sulforafan affects the susceptibility to Oxygen] which affects the expression of MAP3K6 mRNA CTD PMID:30529165 doxorubicin increases expression ISO RGD:1312171 6480464 Doxorubicin results in increased expression of MAP3K6 mRNA CTD PMID:21040762 doxorubicin multiple interactions ISO RGD:1312171 6480464 [[MT1 protein co-treated with MT2 protein] affects the susceptibility to Doxorubicin] which affects the expression of MAP3K6 mRNA CTD PMID:21040762 doxycycline multiple interactions ISO RGD:1312171 6480464 Doxycycline inhibits the reaction [Isoproterenol results in increased expression of MAP3K6 mRNA] CTD PMID:18089841 entinostat increases expression ISO RGD:1312170 6480464 entinostat results in increased expression of MAP3K6 mRNA CTD PMID:27188386 ethanol affects expression ISO RGD:1312171 6480464 Ethanol affects the expression of MAP3K6 mRNA CTD PMID:30319688 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of MAP3K6 mRNA CTD PMID:24793618 folic acid multiple interactions ISO RGD:1312171 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP3K6 mRNA CTD PMID:20938992 furan increases expression EXP 6480464 furan results in increased expression of MAP3K6 mRNA CTD PMID:25539665 , PMID:26194646 genistein increases expression ISO RGD:1312171 6480464 Genistein results in increased expression of MAP3K6 mRNA CTD PMID:24967385 hydrogen sulfide increases expression ISO RGD:1312171 6480464 Hydrogen Sulfide results in increased expression of MAP3K6 mRNA CTD PMID:31843631 indometacin multiple interactions ISO RGD:1312170 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K6 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K6 mRNA CTD PMID:28628672 irinotecan increases expression EXP 6480464 Irinotecan results in increased expression of MAP3K6 mRNA CTD PMID:20097248 isoprenaline multiple interactions ISO RGD:1312171 6480464 Doxycycline inhibits the reaction [Isoproterenol results in increased expression of MAP3K6 mRNA] CTD PMID:18089841 isoprenaline increases expression ISO RGD:1312171 6480464 Isoproterenol results in increased expression of MAP3K6 mRNA CTD PMID:18089841 , PMID:20003209 L-methionine multiple interactions ISO RGD:1312171 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP3K6 mRNA CTD PMID:20938992 methapyrilene increases expression EXP 6480464 Methapyrilene results in increased expression of MAP3K6 mRNA CTD PMID:28935588 methotrexate affects expression ISO RGD:1312171 6480464 Methotrexate affects the expression of MAP3K6 mRNA CTD PMID:18502557 methotrexate decreases expression ISO RGD:1312170 6480464 Methotrexate results in decreased expression of MAP3K6 mRNA CTD PMID:24449571 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1312170 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of MAP3K6 mRNA CTD PMID:25234470 N-nitrosodiethylamine multiple interactions ISO RGD:1312171 6480464 [Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of MAP3K6 mRNA CTD PMID:26778414 naphthalene increases expression ISO RGD:1312171 6480464 naphthalene results in increased expression of MAP3K6 mRNA CTD PMID:18978301 ozone multiple interactions ISO RGD:1312171 6480464 pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MAP3K6 mRNA] CTD PMID:17460151 ozone increases expression ISO RGD:1312171 6480464 Ozone results in increased expression of MAP3K6 mRNA CTD PMID:17095637 , PMID:19555225 paracetamol affects expression ISO RGD:1312171 6480464 Acetaminophen affects the expression of MAP3K6 mRNA CTD PMID:17562736 paracetamol increases expression ISO RGD:1312171 6480464 Acetaminophen results in increased expression of MAP3K6 mRNA CTD PMID:19420014 paraquat increases expression ISO RGD:1312171 6480464 Paraquat results in increased expression of MAP3K6 mRNA CTD PMID:12595580 phenobarbital affects expression ISO RGD:1312170 6480464 Phenobarbital affects the expression of MAP3K6 mRNA CTD PMID:19159669 pirinixic acid increases expression ISO RGD:1312171 6480464 pirinixic acid results in increased expression of MAP3K6 mRNA CTD PMID:18445702 pregnenolone 16alpha-carbonitrile increases expression ISO RGD:1312171 6480464 Pregnenolone Carbonitrile results in increased expression of MAP3K6 mRNA CTD PMID:28903501 sulforaphane multiple interactions ISO RGD:1312171 6480464 [sulforafan affects the susceptibility to Oxygen] which affects the expression of MAP3K6 mRNA CTD PMID:30529165 sulforaphane decreases expression ISO RGD:1312171 6480464 sulforafan results in decreased expression of MAP3K6 mRNA CTD PMID:30529165 tert-butyl hydroperoxide decreases expression ISO RGD:1312170 6480464 tert-Butylhydroperoxide results in decreased expression of MAP3K6 mRNA CTD PMID:15336504 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of MAP3K6 mRNA CTD PMID:31150632 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP3K6 mRNA] CTD PMID:31150632 tetrachloromethane increases expression ISO RGD:1312171 6480464 Carbon Tetrachloride results in increased expression of MAP3K6 mRNA CTD PMID:27339419 tetrachloromethane multiple interactions ISO RGD:1312171 6480464 [Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of MAP3K6 mRNA CTD PMID:26778414 thimerosal decreases expression ISO RGD:1312170 6480464 Thimerosal results in decreased expression of MAP3K6 mRNA CTD PMID:27188386 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of MAP3K6 mRNA CTD PMID:23411599 titanium dioxide increases expression ISO RGD:1312171 6480464 titanium dioxide results in increased expression of MAP3K6 mRNA CTD PMID:23409001 , PMID:27760801 titanium dioxide decreases expression ISO RGD:1312171 6480464 titanium dioxide results in decreased expression of MAP3K6 mRNA CTD PMID:19464567 , PMID:23557971 trichostatin A increases expression ISO RGD:1312170 6480464 trichostatin A results in increased expression of MAP3K6 mRNA CTD PMID:24935251 triclosan increases expression ISO RGD:1312170 6480464 Triclosan results in increased expression of MAP3K6 mRNA CTD PMID:30510588 trimellitic anhydride decreases expression ISO RGD:1312171 6480464 trimellitic anhydride results in decreased expression of MAP3K6 mRNA CTD PMID:19042947 urethane increases expression ISO RGD:1312170 6480464 Urethane results in increased expression of MAP3K6 mRNA CTD PMID:28818685 valproic acid increases expression ISO RGD:1312171 6480464 Valproic Acid results in increased expression of MAP3K6 mRNA CTD PMID:21427059 valproic acid increases methylation ISO RGD:1312170 6480464 Valproic Acid results in increased methylation of MAP3K6 gene CTD PMID:29154799 
Gene-Chemical Interaction Annotations
